AWARD NUMBER: W81XWH-15-1-0021

TITLE: Targeting Neuronal-like Metabolism of Metastatic Tumor Cells as a Novel Therapy for Breast Cancer Brain Metastasis

PRINCIPAL INVESTIGATOR: Siyuan Zhang, M.D., Ph.D.

CONTRACTING ORGANIZATION: University of Notre Dame
Notre Dame, IN 46556

REPORT DATE: March 2017

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.
During this reporting period, we conducted whole tissue clearing based imaging to dissect the interaction between the tumor cell and its brain metastatic microenvironment. We have further developed and refined imaging analysis algorithms and discovered previously underappreciated metastatic phenotype. In addition, through bioinformatics analysis, we identified GAD1 as one of the major driver genes regulating the metabolic shifting of brain metastatic tumor cells. We have the preliminary tested therapeutic potential of using GAD1 pathway inhibitor Vigabatrin in preventing tumor cell proliferation. Encouraged by the promising results, in the next funding year, we are planning to test the therapeutic effects of Vigabatrin using in vivo animal model.
# Table of Contents

1. Introduction .................................................................................. 3
2. Keywords ..................................................................................... 3
3. Accomplishments ......................................................................... 3
4. Impact .......................................................................................... 6
5. Changes/Problems ......................................................................... 7
6. Products ........................................................................................ 7
7. Participants & Other Collaborating Organizations ......................... 7
8. Special Reporting Requirements ...................................................... 8
9. Appendices .................................................................................... 8
1. Introduction

Breast cancer brain metastasis contributed to about 30% of breast cancer-associated fatalities. Patients with brain metastatic relapse have a median survival of less than one year. Most of FDA approved therapies have limited blood-brain-barrier (BBB) penetration. As a consequence, metastatic brain environment becomes a sanctuary site for metastatic tumors. In this proposal, we hypothesize that interactions between colonized tumor cell with brain tissue microenvironment constituents, e.g. reactive brain astrocytes, reprograms the transcriptome profile of tumor cells. Key features of this reprogramming (adaptation) could be exploited for novel brain metastasis treatment. We propose to take of state-of-the-art whole tissue imaging approaches to study the interaction between the tumor cell and metastatic brain environment. We will also determine the functional importance of critical neuronal-like changes during metastatic adaptation and target metastatic colonization of the brain with BBB-permeable neurological drugs. In this project, we propose two specific aims to explore the functional importance of the early metastatic evolution and the feasibility of targeting metastatic evolution by repurposing neurological drugs. Aim 1: Study the spatial and temporal interactions between brain astrocytes and metastatic tumor cells in situ. Aim 2: Pre-clinically investigates the therapeutic efficacy of co-targeting glutamate receptors signaling and breast cancer driver genes.

2. Keywords

Breast cancer, brain metastasis, metastatic outgrowth, brain intravital imaging, brain tissue clearing, glutamate signaling.

3. Accomplishments

What were the major goals of the project? What was accomplished under these goals?

Based on our original SOW, during the previous two funding years, we aim to conduct research as proposed in the original Aim 1. For your easy reference, the original milestones in SOW proposed for year 2 (13-24 months) are listed below as font italics 11pt.

Aim 1.1. Visualize the dynamic interactions between astrocytes and disseminated tumor cells.

Progresses: We have expanded FVB/N-Tg(GFAP.GFP)14Mes/J colonies for intravital imaging. One of the pre-requisite for intravital imaging of brain metastasis is the tumor cell has to seed at brain cortex and with the reach of multiphoton imaging depth (~200 µm). The tumors developed deep inside the brain parenchyma cannot be detected by current technique of intravital imaging. Although we have successful imaged early tumor dissemination and colonization at the brain (as we have reported in Year 1 progress report), we have encountered technical challenges to detect enough tumors that form and outgrow underneath our cranial imaging window. As the anatomical location is completely random, this observation is not completely unexpected. After multiple attempts and careful consider the risk and potential benefits, we decided to use intravital imaging technique to focus on early stage colonization only. The late stage metastatic development will be better addressed using our tissue clearing based imaging approaches (see below).

Aim 1.2: Multiplexed molecular phenotyping of the metabolic and survival signaling of metastatic tumor
cells in situ.

**Aim 1.3:** Exploring the functional importance of glutamate signaling in early colonization.

1) Collect brain metastasis samples from multiple animal cohorts
2) Clear tissue specimen
3) Major markers are IF stained
4) 2-photon deep tissue imaging are performed
5) Reconstruction of multiplexed 3D brain metastasis and data analyses

**Progresses:** In the first year for funding period, we were able to establish cutting-edge imaging approaches to obtain multiplex immunofluorescence stained brain tissue. After staining and whole tissue imaging, we were able to 3D co-registration of multiple metastatic landscape components with high spatial resolution on a global scale of dimensions up to approximately 4000µm x 4000µm x 3000µm. In the past funding year, we continue collaborate with Danny Chen's group at Department of Computer Science and Engineering to further develop the imaging analysis algorithm to unbiasedly analysis the large imaging dataset. We have successfully developed new algorithms and discovered previously underappreciated angiogenesis events during the brain metastasis progression. The fruitful interdisciplinary collaboration has resulted in three publications and three patents disclosures.


**Aim 1.3:** Exploring the functional importance of glutamate signaling in early colonization.

**Aim 2.1.** Investigate the preclinical efficacy of Talampanel plus Lapatinib combinatorial therapy in the treatment of breast cancer brain metastasis in vitro.

1) Establish the optimal in vitro combination dose
2) Perform multiple round of in vitro cell proliferation assays
3) Reveal the major molecular mechanism of combinatorial treatment

**Progresses:**
Our preliminary observation suggested that an up-regulation of glutamate receptor on tumor cells metastasized to the brain. Based on this observation, in the original proposal, we hypothesized that targeting glutamate receptor using brain permeable drug might potentially prevent brain metastasis. In the past funding year, we first conducted systematic bioinformatics analysis by comparing the transcriptome profile brain metastasis and its primary tumor counterpart. Considering the up-regulation of glutamate receptor we observed, we first focused on curated metabolism related genes using a publically available cDNA microarray dataset (GSE19184),
containing gene expression data generated from either primary xenograft tumors or brain metastases counterpart. Interestingly, we observed a global down-regulation of the majority of metabolism-related genes in brain metastatic tissues compared with respective primary tumors. In contrast, only a small set of metabolism related genes were up-regulated in brain metastases, suggesting that brain metastases engage a specific metabolic program that is vital for sustaining their energy needs. We performed GSEA to further determine the functional implications of the tumor metabolic shift. Interestingly, despite the majority of metabolism related gene sets were negatively enriched in the brain metastatic tumors, only one gene set (REACTOME: GABA synthesis, release, reuptake, and degradation) was significantly enriched in the brain metastatic tumors (Fig. 1a). γ-aminobutyric acid (GABA) is an inhibitory neurotransmitter primarily found in GABAergic neurons. The enrichment of GABA signaling in brain metastatic tumor cells suggests that the metastatic tumor cells might adapt and shift to more neuronal-like signaling to thrive in the brain microenvironment. Examining the "REACTOME: GABA synthesis, release, reuptake, and degradation" gene set further revealed glutamate decarboxylase 1 (GAD1) as among the only three significantly up-regulated genes in brain metastases (Fig. 1b). GAD1 catalyzes the production of GABA from L-glutamic acid and is primarily found in the cytosol in order to provide an intracellular source of GABA for cell metabolism. We reasoned that the GAD1-mediated GABA pathway, downstream of the glutamate receptor, could be the primary method for utilizing glutamine, as an energy source in metastatic tumor cells. To test this hypothesis, we performed GAD1 knockdown experiments under the co-culture of brain microenvironmental cells (primary brain glia cells). Knocking GAD1 significantly decreased tumor cell's survival advantage under glia cell co-culture (Fig. 1c).

The reliance on brain microenvironment-dependent GAD1 upregulation to drive glutamine metabolism and cell proliferation represent a novel therapeutic opportunity for brain metastasis treatment. Modulation of GAD1-mediated GABA metabolism has been clinically exploited previously as an anti-seizure therapy. One such drug, vigabatrin, targets GABA metabolism by inhibiting GABA transaminase (GABA-T), an enzyme directly downstream of GAD1. Vigabatrin thus functions to block GABA flux into the TCA cycle. Due to the essential role of GAD1-mediated GABA signaling in metastatic outgrowth, we plan to test vigabatrin, instead of Talampanel, as a potential therapy for decreasing metastatic outgrowth. Preliminary in vitro testing showed that...
treatment of vigabatrin reduces tumor cell proliferation in vitro (Fig. 1d). Above observations gave a strong rationale to test vigabatrin in vivo. We are currently in a process of revising IACUC/ACRUO protocols.

What opportunities for training and professional development has the project provided? This project provides a unique multidisciplinary training opportunity for my trainees who traditionally trained as classic cell/cancer biologists. In the past funding year, the whole tissue imaging aspects this project continued to provide unprecedented opportunities for my graduate students to interact with Computer Engineer to develop novel ways to analyze large imaging data. On the biology side, my trainees have learned modern bioinformatics tools in order to analyze microarray/RNA-seq data (both publically available and generated by our lab). The new direction as reported above is a direct results of creative exploration by the talented trainees in my lab.

How were the results disseminated to communities of interest? The research products generated from this project has been presented at the national conferences, including 19th International Conference on Medical Image Computing and Computer-Assisted Intervention, Society of Neuroscience Annual Meeting 2016. An abstract has also been submitted to 2017 AACR meeting. In addition, we continue to participate community outreach activities, such as Notre Dame Day, to disseminate some of our exciting results to lay public. We have collaborated with local high school (Penn High School) to use our tissue clearing and 3D imaging as powerful tools to engage high school students who are interested in STEM career path.

What do you plan to do during the next reporting period to accomplish the goals?

In the next funding year, we will continue develop our imaging platform to obtain insight on molecular mechanisms of metabolic shifting. We aim to achieve the following goals:

1) Start to explore the functional importance of metabolic genes (GAD1) in regulating brain metastasis success.
2) Investigate the mechanisms of GAD1 up-regulation at brain microenvironment.
3) In vivo testing the therapeutic efficacy of vigabatrin in treatment or preventing breast cancer brain metastasis.

4. Impact...........................................................................................................

What was the impact on the development of the principal discipline(s) of the project? As we have reported last year, in this project we are taking highly innovative imaging approach to study brain metastasis. We are the first group that applies this whole tissue imaging methodology to study cancer metastasis. From clinical translational perspective, identify GAD1 is significant. Because repurposing FDA approved BBB-permeable vigabatrin (targeting GAD1 pathway) is a relatively safe metastasis prevention drug and highly clinically translatable. If proven to be successful, similar concepts can be explored for fast clinical repurposing of other FDA approved drugs for cancer therapy.

What was the impact on other disciplines?
To analyze the big 3D imaging dataset effectively, we are collaborating with our collaborators in the computational engineering department who are specialized in imaging progressing to develop robust image segmentation/analysis methods. This collaborative effort will lead to more powerful tools for traditional biologist in cancer biology and related field. As a direct result of this project, we have filed two patent disclosure related to medical image analysis (see below).

**What was the impact on technology transfer?**
Base on the work from this project, we have file three patent disclosures via Notre Dame Technology Transfer Office:
1) Repurposing Current Neurological Drugs for Anti-Metastatic Brain Tumor therapy
2) A method for fast and accurate removal of background noise in 3D microscopy images
3) A new method for segmentation of glial cells in 3D microscopy images

**What was the impact on society beyond science and technology?**
Nothing to report

5. Changes/Problems.................................................................

Nothing to report

6. Products.................................................................

This project has led to three publications:

We are in the process of summarizing our findings related to GAD1 into a manuscript entitled: “GAD1 Upregulation Programs Aggressive Features of Cancer Cell Metabolism in the Brain Metastatic Microenvironment”. This award is acknowledged.

7. Participants & Other Collaborating Organizations............

**What individuals have worked on the project?**
<table>
<thead>
<tr>
<th>Name:</th>
<th>Siyuan Zhang</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>PI</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>A-1276-2014</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>3</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>As the PI of this project, Dr. Zhang oversees the project design and data interpretation.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>DoD (this award)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Patricia Schnepp</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Graduate student</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>NA</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>12</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Patricia’s thesis work primarily focuses on this project. She plays a major role in conducting in vitro and in vivo biology experiments and bioinformatics analysis.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Partially funded by DoD (this award) and Walther Foundation for Cancer Research (pre-doctoral fellowship)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Ian Guldner</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Graduate student</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>NA</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>3</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Ian primarily focuses on developing tissue imaging pipeline and perform imaging data analysis.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Partially funded by DoD (this award) and departmental teaching assistantship.</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Name:</th>
<th>Qingfei Wang</th>
</tr>
</thead>
<tbody>
<tr>
<td>Project Role:</td>
<td>Postdoctoral Fellow</td>
</tr>
<tr>
<td>Researcher Identifier (e.g. ORCID ID):</td>
<td>NA</td>
</tr>
<tr>
<td>Nearest person month worked:</td>
<td>6</td>
</tr>
<tr>
<td>Contribution to Project:</td>
<td>Qingfei is responsible for bioinformatics analysis, co-culture experiment, in vivo mouse work.</td>
</tr>
<tr>
<td>Funding Support:</td>
<td>Partially funded by DoD (this award) and departmental funds.</td>
</tr>
</tbody>
</table>

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

Nothing to report
What other organizations were involved as partners?

Nothing to report

8. Special Reporting Requirements............................................

Nothing to report

9. Appendices..............................................................................

Manuscript summarizing the research findings of brain metastasis landscape:

An Integrative Platform for Three-dimensional Quantitative Analysis of Spatially Heterogeneous Metastasis Landscapes

Ian H. Guldner1,2,*, Lin Yang3,*, Kyle R. Cowdrick1,2, Qingfei Wang1,2, Wendy V. Alvarez Barrios1,2, Victoria R. Zellmer1,2, Yizhe Zhang3, Misha Host1,2, Fang Liu2,4, Danny Z. Chen2,3 & Siyuan Zhang1,2

Metastatic microenvironments are spatially and compositionally heterogeneous. This seemingly stochastic heterogeneity provides researchers great challenges in elucidating factors that determine metastatic outgrowth. Herein, we develop and implement an integrative platform that will enable researchers to obtain novel insights from intricate metastatic landscapes. Our two-segment platform begins with whole tissue clearing, staining, and imaging to globally delineate metastatic landscape heterogeneity with spatial and molecular resolution. The second segment of our platform applies our custom-developed SMART 3D (Spatial filtering-based background removal and Multi-chAnnel forest classifiers-based 3D ReconsTruction), a multi-faceted image analysis pipeline, permitting quantitative interrogation of functional implications of heterogeneous metastatic landscape constituents, from subcellular features to multicellular structures, within our large three-dimensional (3D) image datasets. Coupling whole tissue imaging of brain metastasis animal models with SMART 3D, we demonstrate the capability of our integrative pipeline to reveal and quantify volumetric and spatial aspects of brain metastasis landscapes, including diverse tumor morphology, heterogeneous proliferative indices, metastasis-associated astrogliosis, and vasculature spatial distribution. Collectively, our study demonstrates the utility of our novel integrative platform to reveal and quantify the global spatial and volumetric characteristics of the 3D metastatic landscape with unparalleled accuracy, opening new opportunities for unbiased investigation of novel biological phenomena in situ.

Tumor metastasis is orchestrated by the interplay between genetically heterogeneous cancer cells and a spatially and compositionally heterogeneous tumor microenvironment (TME, also referred to as the metastatic niche)1-5. Metastatic cells and the metastatic TME – together, termed the metastatic landscape – are composed of several different cell types that display an ever-evolving heterogeneity throughout metastatic progression6-8. It has been envisioned that spatially compartmentalized metastatic niches differentially regulate metastatic progression6-8. For example, the role of astrogliosis during brain metastasis formation has been debated for decades9,10. Limited by two-dimensional (2D) in vitro culture and histology methods, previous studies were unable to fully describe the spatial heterogeneity of astrogliosis or deduce the functional implications of astrogliosis during brain metastasis progression in situ within large, intact tissue samples. Similarly, angiogenesis, a hallmark of cancer, is crucial to maintain brain tumor outgrowth, such as in gliomas11,12. Yet, the requirement and characterization of angiogenesis during brain metastasis progression remain largely controversial10. Because only a small fraction of the total vasculature can be captured in a single standard histological slice, even the most concrete brain metastasis vascularisation data draw speculative conclusions. Despite the significance of examining spatial aspects of

1Department of Biological Sciences, College of Science, University of Notre Dame, Notre Dame, IN 46556, USA. 2Mike and Josie Harper Cancer Research Institute, University of Notre Dame, 1234 N. Notre Dame Avenue, South Bend, IN 46617, USA. 3Department of Computer Science and Engineering, College of Engineering, University of Notre Dame, Notre Dame, IN 46556, USA. 4Department of Applied and Computational Mathematics and Statistics, College of Science, University of Notre Dame, Notre Dame, IN 46556, USA. *These authors contributed equally to this work. Correspondence and requests for materials should be addressed to S.Z. (email: szhang8@nd.edu)
heterogeneous metastases in their metastatic niche, technical barriers have impeded efforts to dissect the contribution of diverse spatial components of the metastatic landscape in situ on a global three-dimensional (3D) scale with molecular-level resolution.

The recent boom of whole tissue clearing techniques presents us with an unprecedented opportunity to dissect metastatic heterogeneity in situ. Tissue clearing permits a holistic, 3D view of tissue, which is particularly useful to image two metastatic landscape components – astrocytes and vasculature – that cannot be captured in a single plane and have diverse or highly speculated roles in metastatic progression. Furthermore, the 3D perspective provided by tissue clearing allows spatial analysis, which can provide novel insights into biological phenomena. While tissue clearing provides an unmatched opportunity to explore the metastatic landscape, the massive volumetric datasets derived from whole tissue imaging impose new challenges on the image analysis of multiple genetic events with statistically significant biological implications. In this study, we developed and applied an integrative platform including a 3D whole brain imaging approach, consisting of whole tissue clearing, staining, and imaging, followed by customized computer-assisted quantifications. We developed SMART 3D (Spatial filtering-based background removal and Multi-chAnnel forest classifiers-based 3D ReconsTruction), a multi-faceted image analysis pipeline, to observe and quantify phenotypic metastatic landscape heterogeneity in situ with spatial and molecular resolution. Our implementation of our integrative platform to globally analyze the heterogeneous metastasis landscape of brain metastases demonstrates the feasibility of quantitative, multiplexed 3D analysis in situ from the molecular level to the whole organ scale. Furthermore, our study asserts the promise of such analysis in revealing unique spatial patterns of metastasis that will lead to novel functional and molecular insights into the dynamic nature of metastasis.

Results

Global imaging of multiple metastatic landscape features with molecular resolution. We streamlined a whole tissue clearing, staining, imaging, and computation analysis pipeline to quantitatively analyze and thereby enable the elucidation of the functional impact of phenotypic heterogeneity of the metastatic landscape on metastatic outgrowth (Fig. 1a, Supplementary Fig. S1a). The first segment of our pipeline (Fig. 1a, top), consisting of whole tissue clearing, staining, and imaging, ultimately conquers the long-standing challenge of capturing multiple genetic events in their native 3D context in situ to allow a holistic view of the tissue and its compositional and spatial heterogeneity. Tissue clearing and refractive index matching rendered the brain lipid-free and optically transparent, allowing for thorough multiplexed molecular phenotyping of large tissue sections (Supplementary Fig. S1b,c and Supplementary Video S1). Further, cleared brain tissue permitted an approximate five-fold increase in imaging depth from ~500 μm (Fig. 1b, left) to ~3000 μm (Fig. 1b, right). Distinguished from previous tissue clearing-based studies, which primarily relied on transgenic mice that express fluorescent proteins, our approach relied on multiplexed staining for proliferative nuclei, metastatic tumor cells, and TMEM components (e.g., astrocytes), allowing 3D co-registration of multiple metastatic landscape components with high spatial resolution on a global scale of dimensions up to approximately 4000 μm × 4000 μm × 3000 μm (Fig. 1c and Supplementary Video S2). This exponential increase of data content enabled us to reconstruct the brain metastasis landscape in 3D, providing new, exceptionally accurate perspectives on phenotypic heterogeneity, such as the highly irregular tumor morphology that is masked in two-dimensional images (Fig. 1d). We were able to glean detailed information from large, continuous tissue structures, such as blood vessels (Supplementary Fig. S1d), while maintaining high 3D resolution at the cellular level, such as one single extravasated metastatic cell (Fig. 1e), and subcellular details, such as dividing nuclei (Fig. 1f).

Spatial background removal and forest classifiers-based multi-channel 3D reconstruction (SMART 3D: Spatial Multi-chAnnel ReconsTruction 3D). Accurate image segmentation is a prerequisite for quantitative analysis of the spatial relationship between metastatic cells and the metastatic niche. The second and third segments of our integrative pipeline (Fig. 1a, bottom) tackle both the extensive problems (e.g., background removal, multi-channel reconstruction) faced in processing large 3D datasets with multiple channels as discussed in detail below. Despite a significant increase of 3D imaging depth enabled by tissue clearing, strong auto-fluorescence background (noise signal) and inhomogeneous fluorescent staining across the whole tissue significantly limit the applicability of existing 2D computational algorithms for accurate segmentation and visualization of large, multi-channel volumetric 3D datasets. Thus, the first step of our image analysis aimed to remove the background noise in the 3D datasets.

We developed a new approach that combines the spatial filtering method and optimization-based methods for this background removal problem on 3D images. Due to wide variations in the sizes of foreground objects in 3D datasets, it is very difficult to select one single appropriate window size or ball size for the spatial filtering method and the rolling ball algorithm. We applied percentile filtering with a window size that is slightly larger than the size of the smallest object (e.g., the size of a cell) in the image to estimate a rough background. Subsequently, we used unsupervised one-class learning to detect errors in this rough estimation (Fig. 2a). Finally, these errors were corrected in the re-estimation process and the refined background estimation was obtained for generating a noise-reduced image. The processing speed of our new background removal method is comparable to the algorithm yields the unprecedented efficiency in removing background while preserving fine structural details (e.g., fine processes of astrocytes) (Fig. 2a, bottom panel).

To compute voxel-level image segmentation with high tolerance of inhomogeneous fluorescent staining, we extracted feature vectors representing each voxel’s appearance and texture from multiple channels and concatenated the feature vectors from different channels into a multi-channel feature vector (MFV) (Fig. 2b). Next, we formulated the voxel-level segmentation problem as a classification problem (Fig. 2c). Several classifiers were trained to determine whether a voxel belongs to a specific type of foreground (e.g., tumor cells, astrocytes, blood...
Figure 1. 3D Whole Tissue Imaging of the Brain Metastasis Landscape with Molecular Resolution. (a) Schematic of our integrative platform consisting of whole tissue clearing, staining, and imaging and SMART 3D (image processing and quantification). (b) Comparison of multiphoton-imaging depth without (left) or with (right) optical tissue clearing. 2D slices are extracted from indicated depths in the tissue-cleared z-stack to demonstrate image quality at various imaging depths. (c) Multiphoton image of 3D global view (2500 μm × 3500 μm × 3000 μm) of optically cleared mouse brain with multiple MDA-MB-231.Br-derived metastases. Red: anti-GFAP; blue: DAPI. (d) 2D multiphoton image (top) and 3D surface generated image (bottom) of PNA.Met1 brain metastases stained with anti-cytokeratin 8 (K8). (e) 3D multiphoton image of astrocytes (GFAP, red) of the blood brain barrier (left) and astrocyte interaction with MDA-MB-231.Br metastatic cells (right). Blue arrows point to astrocytes, and yellow arrows point to metastatic cells. (f) 3D multiphoton image of PNA.Met1 brain metastasis (K8, green) and EdU-tagged nuclei (orange) (top) and enlarged view of dividing nuclei (bottom).
Figure 2. Spatial Filtering-Based Background Removal and Multi-Channel Forest Classifiers-Based 3D (SMART 3D) Reconstruction of Metastatic Heterogeneity. (a) Schematic of the background removal process. Arrow points to fine astrocyte processes preserved by this method. (b) Schematic of multi-channel feature extraction. (c) Schematic of the process of voxel-level segmentation based on random forest classification. (d) Image of DAPI stained MDA-MB-231.Br brain metastases sample before (top left) and after (top right) DAPI cluster-based tumor segmentation and surface generation. Color codes represent individually identified tumors. Bottom panel: whole spectrum of individual morphologically heterogeneous tumors. (e) Image of DAPI (blue) and K8 (green) stained PNA.Met1 brain metastases before (top left) and after (top right) K8/DAPI-based segmentation and surface generation. Bottom panel: whole spectrum of individual morphologically heterogeneous tumors.
vessels, etc.) or the background based on MFV. These classifiers (200 trees and 2 candidate features in each node) were then applied to every voxel in the 3D volumetric datasets to generate the segmentation of desired features (Fig. 2c). To test the accuracy of the classifier, we manually labeled 10 slices for each different component (e.g., tumor, astrocyte, EdU proliferation marker, and blood vessel) and used labeled features as the ground truth. The accuracy was then measured by the F1 score of 10-fold cross validation. F1 score is the harmonic mean of precision and recall, and it is a widely used measure to evaluate the performance of the classifier22. According to the F1 score evaluation, volume quantification errors are approximately \(-3.35\%,-0.03\%\), +8.51\%\), and 1.86\% for tumors, astrocytes, proliferating cells, and blood vessels, respectively (Supplementary Table S1). Finally, we applied the SMART 3D pipeline to a series of 3D multi-channel datasets to reconstruct and quantify the metastasis landscape (Figs 2d and 3–5).

Heterogeneous morphology of breast cancer brain metastases. To test the robustness of SMART 3D, we generated experimental brain metastases using two breast cancer brain metastasis models with distinct morphologies: MDA-MB-231-brain-seeking (Br) human breast cancer cells in an immunocompromised (Rag1\(^{-/-}\) mouse and PNA.Met1 murine breast carcinoma cells in an FVB host. We stained metastasis-burdened samples with the epithelial cell-specific marker cytokeratin 8 (K8) antibody to identify breast cancer brain metastases, as K8 is absent in normal cerebral cortex (Supplementary Fig. S2a). In addition, tumor cell nuclei displayed unique pleomorphism distinct from neural tissue nuclei, allowing for further nuclear-based tumor cell identification. Our SMART 3D algorithm was adaptive to diverse tumor morphologies in 2D and 3D (Supplementary Fig. S2b,c) and proved to be robust as indicated by the overlap between the original 3D images and the computationally segmented voxels (Supplementary Fig. S2d). Surface renderings of the SMART 3D-segmented metastases within the same metastatic niche revealed a previously underappreciated array of morphological heterogeneity (Fig. 2d,e). The MDA-MB-231.Br metastases are highly branched, reflecting their exclusive growth along brain vasculature (vesSEL co-option)23, whereas PNA.Met1 metastases form irregularly shaped clusters (Supplementary Video S3), reflecting the morphology of brain metastases observed in the clinic. Within the same metastatic niche, the volumes of metastatic tumors are extremely diverse, ranging from 9.6–857.7 \(\times 10^3\) \(\mu\)m\(^3\) to 155.3–8074.0 \(\times 10^3\) \(\mu\)m\(^3\) for MDA-MB-231.Br and PNA.Met1 tumors, respectively. This broad spectrum of metastasis volumes suggested a wide range of developmental stages of metastatic lesions within the same TME.

Metastasis developmental stage shapes a non-linear proliferative heterogeneity. Taking advantage of the multi-channel spatial segmentation and quantification capacities of SMART 3D, we next surveyed the proliferation status of every tumor cell in each metastasis by 5-ethynyl-2’-deoxyuridine (EdU) detection24. Both metastasis models displayed a wide spectrum of proliferative indices, from less than 1\% to as much as 56\%. Interestingly, metastases of similar sizes had very disparate proliferative indices (Fig. 3a,b). Kernel density estimation (KDE, “Gaussian”) for MDA-MB-231.Br metastases showed that small and medium metastases had a wide range of proliferation scattered across proliferative indices (0–0.3) and large metastases had a relatively uniform level of proliferation concentrated between 0.1 and 0.2 proliferative indices. The difference between the variance of proliferation between large metastases (Log\(_10\) tumor volume > 5.0) and small and medium metastases are statistically significant (\(p = 0.012\), F-test) (Fig. 3c). KDE (“Gaussian”) for PNA.Met1 metastases revealed a different pattern of proliferation, with a wide range of heterogeneity for small and large metastases, but a narrower range of proliferation for medium metastases primarily concentrated at 0.2 proliferative index (Fig. 3d, left). Interestingly, a parabola-shaped trend (\(p = 0.003\), quadratic regression) fit the data of tumor proliferative index versus metastasis volume, in which the vertex of the parabola was within the medium-sized metastasis range and approached a proliferative index of 0.15. Notably, two tumors (i.e., tumors 14 and 19) fell below the vertex and had negligible proliferation (Fig. 3d, right).

Leveraging the spatial aspect of our 3D imaging approach, we next probed the spatial distribution of proliferative cells within metastases. We did so by performing concentric zone analysis in which we analyzed the proliferative indices of concentric 10 \(\mu\)m-thick volumetric zones from the tumor surface to the tumor core (Fig. 3e). Linear regression analysis demonstrated distinct proliferative kinetics in which small tumors have a sharp proliferative index drop-off approaching the tumor core (proliferative index drops from \(\sim 0.5\) to 0.12, \(p < 0.001\)), while the tumor core remains proliferative in medium and large sized tumors (Fig. 3f). Notably, there is extensive proliferative heterogeneity both among individual metastases and the zones within individual metastases (Fig. 3g). Even similarly sized tumors have dramatically different maximum proliferative indices (e.g., tumors 18 and 19) and proliferative patterns among zones from the surface to the core (e.g., tumors 16–18).

Metastasis-induced astrogliosis influences proliferative heterogeneity of tumors. In his “seed and soil” hypothesis, Stephen Paget first proposed that the tumor microenvironment is both essential and important in metastatic seeding and outgrowth25,26. To explore microenvironmental factors that potentially influence metastatic outgrowth while taking advantage of the holistic view provided by 3D imaging, we first examined the astrogial response to brain metastases, a response that 2D imaging insufficiently captures in terms of astrocyte morphology and spatial distribution (Supplementary Fig. S3). Previous studies have suggested that the astroglial response promotes metastatic outgrowth26–33. To accurately characterize the astrocyte response to brain metastases, we imaged the astrogial response in 3D to obtain complete astrocyte morphology in exquisite detail (Supplementary Fig. S3) and further applied SMART 3D to clearly distinguish anti-GFAP staining from background noise in 2D and 3D (Supplementary Fig. S3). This enabled us to reconstruct and quantitatively analyze spatial astrogliosis patterns on a global scale (Fig. 4a). Qualitative analysis of astrogliosis revealed that astrocyte coverage of tumors was not spatially uniform around metastases and the volume of astrogliosis was variable among metastases in both the PNA.Met1 model (Fig. 4b) and the MDA-MB-231.Br model (Supplementary Fig. S4). Notably, the early astrogial response (gliosis index) appeared to be negatively correlated with metastasis.
proliferation ($r = 0.648$) (Fig. 4d). When metastatic outgrowth progressed, the level of astrogliosis was positively correlated with the proliferation indices of metastases in both medium ($r = 0.700$) and large ($r = 0.656$) tumor groups (Fig. 4d,e). Interestingly, two medium to large-sized metastases (i.e., tumors 14 and 19) have negligible gliosis, and also have extremely low proliferative indices. Importantly, tumor 19, which had no associated astrogliosis, may indicate a different mechanism of proliferation.
Figure 4. Heterogeneous Astrocyte Response to and Influence on PNA.Met1 Brain Metastases. (a) 3D multiphoton image of astrocytes (GFAP+, red) associated with PNA.Met1 brain metastases (K8, green) (left), and corresponding 3D segmentation of the astrocytes (right). (b) Representative surface generated images of PNA.Met1 tumors (green) and various levels of associated astrocytes (red). (c) Schematic representation of the gliosis zone. Zone depth = 24 μm, the maximum spatial size of one astrocyte. (d) Regression plot of the relationship between the proliferative index and the square root (sqrt) of the gliosis index for small (left), medium (middle), and large (right) PNA.Met1 brain metastases. Gliosis index = Total astrocyte voxel volume/Total zone voxel volume. (e) Representative surface generated images of PNA.Met1 metastases (green) and EdU-tagged nuclei (orange) (left column) and the metastases and the associated astrocytes (red) (right column). (f) Surface generated image of global view of PNA.Met1 metastases (various colors) and associated astrocytes (red), highlighting tumors extremely low gliosis (blue; #14 and #19).

Astrogliosis, was not proliferative, whereas similarly sized tumors (i.e., tumors 17, 20, and 21) within the same metastatic niche as tumor 19 were surrounded with reactive astrocytes and thrived with active proliferation (Fig. 4f), suggesting a role of astrogliosis in sustaining metastasis growth. Unlike PNA.Met1 metastases, global analyses of MDA-MB-231.Br metastases showed no clear correlation between gliosis index, proliferation index, or metastasis size (Supplementary Fig. S4), indicating a non-essential role of astrogliosis in MDA-MB-231.Br
Heterogeneous spatiotemporal angiogenic response to brain metastases. Patterns of brain tumor and brain metastasis angiogenesis are highly debated primarily due to a lack of approaches that can capture blood vessels in their entirety in situ. By taking advantage of our tissue clearing-based imaging approach and SMART 3D analysis pipeline, we explored the global intratumoral and peritumoral angiogenesis patterns in 3D (Fig. 5a). Qualitative analyses showed extensive, tortuous tumor-associated vasculature comparable to previous experimental and clinical observations. We also observed highly branched vessels covering the tumor surfaces and few but large infiltrating blood vessels inside the tumors, which were previously underappreciated features (Fig. 5b, Supplementary Fig. S5a, Supplementary Video S4). To reveal the global spatial relationship of each tumor cell to the surrounding blood vessels, we further quantified the spatial distance from each tumor cell voxel to the nearest blood vessel (Fig. 5c). Although metastatic tumors analyzed contain different numbers of tumor cells (n = 264 for tumor D and n = 1136 for tumor A), as measured by the mode frequency of density curve, most tumor cells were located less than 40 μm away from the nearest blood vessel, a pattern consistent among all metastasis sizes, which is significantly closer than the previously documented limit (100 μm) derived from 2D histology studies.

To further examine the spatial patterns of angiogenesis, we performed concentric zone analysis covering zones from the core of metastases to the closest vessel outside the metastases (Supplementary Fig. 5b,c). Despite different tumor sizes, the maximum relative vascularisation index inside each tumor is approximately 0.02. The vascularisation index of smallest tumor (Tumor D) progressively declined from the tumor surface to the core. Tumor C had an increase of relative vascular volume approaching the middle zone, after which point the relative vascular volume sharply decreased, producing an inverted parabola, implying de novo angiogenesis inside the tumor.

Finally, to test whether the SMART 3D-based angiogenesis analysis could potentially be used to evaluate anti-angiogenic therapies, we treated brain metastases-bearing mice with multi-kinase inhibitor Sorafenib, a FDA approved small molecule inhibitor which has been shown to be blood brain permeable and enter the brain and exhibit encouraging efficacy in treating brain metastases derived from renal cell carcinoma. Surprisingly, despite a discernable decline of peritumoral angiogenesis, the intratumoral mean vascular density (MVD) did not significantly decrease (Fig. 5d).

Discussion
Metastatic colonization and outgrowth are believed to be spatially heterogeneous and temporally dynamic. While current state-of-the-art single-cell sequencing technologies have made strides toward understanding the genetic basis of tumor heterogeneity, deciphering the spatial and compositional heterogeneity of metastasis remains heavily reliant on conventional 2D histology. It is imperative to develop and integrate novel techniques from multiple disciplines to explore metastasis from spatial perspectives. In this study, we sought to do so by further developing and integrating cutting-edge technologies from the fields of both neuroscience and computational science. Our unique, integrative approach combining whole tissue clearing, staining, and imaging, with computer-assisted segmentation and quantifications (SMART 3D) provided us leverage in studying the metastatic landscape with unparalleled accuracy. Specifically, we have demonstrated the power of whole tissue imaging in delineating astonishing morphological diversity of metastatic tumors. More importantly, we demonstrated the feasibility of using multiplexed immunostaining to molecularly characterize the spatially heterogeneous metastasis landscape. With further refinement of whole tissue staining procedures and validation of antibodies for cleared tissue, we expect multiplexed molecular staining will produce unprecedented mechanistic insight into many biological phenomena in the near future.

With the maturation of tissue clearing techniques, using this whole tissue imaging approach to explore tissue structure or tumor heterogeneity becomes highly desirable for many laboratories. However, quantitative analysis of 3D volumetric datasets that are terabytes in size poses new, significant challenges. Our study provides one possible solution (SMART 3D) for quantitative analysis of 3D, multi-channel volumetric data. First, by developing and applying a spatial background removal algorithm, we effectively removed inhomogeneous fluorescent background present in most biological samples and further induced by immunostaining. Effective background removal in 3D images forms the foundation for downstream segmentation and quantification. Second, we constructed a machine learning (forest classifiers) based multi-channel 3D reconstruction pipeline by integrating biologically meaningful factors annotated by biologists and computational features intrinsic to 3D volumetric datasets. In our experience, applying this machine-learning pipeline is critical to more effectively extract and recover structural information from large 3D volumetric data that inevitably varies significantly within the same dataset. Lastly, our study demonstrated how our integrative whole tissue imaging and analysis platform could help biologists generate statistically significant correlations and discern previously unknown patterns that imply novel hypotheses of molecular mechanisms to be formulated and further explored.

Our study applying our integrative pipeline revealed a previously underappreciated heterogeneity in the metastatic landscape, and our spatial analysis of the metastasis landscape also shed light on how the TME impacts metastatic outgrowth. Two examples of such microenvironmental factors/processes we investigated in our study are astrocytes (in the process of astrogliosis) and vasculature. Through cross-referencing metastasis proliferation, tumor developmental stage, and astrogliosis, we revealed a dual, stage-dependent role of astrocytes on metastatic outgrowth (Fig. 4). Through global proliferation analysis coupled with spatially defined blood vessel density, we noted that the majority of cells in metastatic tumors are located in close proximity (between 10–20 μm) to blood vessels (Fig. 5c). More interestingly, the anti-angiogenic treatments led to a divergent spatial pattern of blood vessel distribution, which should be closely examined in the future studies. Collectively, results from our unbiased
Figure 5. Heterogeneous Spatial and Temporal Vasculature Response to PNA.Met1 Metastases. (a) 3D multiphoton image of metastasis-associated vasculature (top) and associated 3D segmentation image (bottom). (b) 3D images of metastasis-associated vasculature (red) before (top left) and after (top right) surface generation of vasculature, with a focus on vasculature on metastasis surface (bottom left) and infiltrating vasculature (bottom right). (c) Kernel density estimation (KDE) plot for the distance of each tumor cell voxel to the nearest blood vessel for tumors A, B, C, and D. \( n \): number of tumor cells. (e) Surface generated image of a PNA.Met1 brain metastasis (transparent green) and associated vasculature (red) treated with Sorafenib (left) and plots of the mean vasculature density within the tumor (intratumoral) and outside the tumor (peritumoral) for Sorafenib and control-treated mice. Peritumoral zone = spatial distance within 100 μm from tumor surface.
global approach further underscore a critical role of metastatic niche environmental factors and their potential role in sustaining metastatic outgrowth or metastatic dormancy. These observations will lead to new avenues for further functional investigations of novel mechanisms of metastasis.

With the continuous development of new, better tissue clearing methods and optics technology, our platform and SMART 3D will only grow in relevance. Our platform is designed to be able to integrate any given tissue clearing method, and SMART 3D is capable of processing and analyzing image data sets derived from a variety of 3D, multi-channel high content imaging strategies. In this study, we demonstrated the ability of SMART 3D to adapt to analyzing datasets derived from the most recently developed tissue clearing methods, including CUBIC 2, PACT, and ScaleAB. Furthermore, our platform will become even more vital for researchers applying new tissue clearing methods, which are increasingly compatible with multiple antibodies (Supplementary Table S2). Increasing ability to simultaneously stain for multiple markers will dictate the use of several channels during image acquisition, necessitating the multi-channel processing and analysis of which our platform is uniquely capable. Advanced optics systems for imaging will decrease image acquisition time while increasing the data content obtained, which SMART 3D will be able to process and analyze. Our integrative pipeline, unlike most methods and technologies, promises to become increasingly relevant with time and provide a scaffold by which researchers can tackle complex biological questions.

Taken together, we developed an integrative platform for 3D quantitative analysis of the spatially and compositionally heterogeneous metastasis landscape. Using whole tissue multiplexed staining and fluorescence imaging coupled with our SMART 3D image analysis pipeline, we demonstrated intriguing patterns of spatial heterogeneity of the metastatic landscape. By integrating multidisciplinary expertise, our proof-of-concept study, the first of this type, further demonstrates the necessity of examining metastases in 3D in situ, the practicality of this approach, and the novel concepts and discoveries that may be derived from 3D quantitative image analysis.

Methods

**Cell Culture.** The parental MDA-MB-231 cells were purchased from ATCC. MDA-MB-231.Br cell line was developed by in vivo selection of brain tropin derivatives for a minimum of three rounds through intra-cardiac injection. PNA Met1 cell lines were established from spontaneous primary murine mammary tumors from MMTV-PyMT transgenic mouse (FVB background). MDA-MB-231.Br cell line was cultured in DMEM F12 medium supplemented with 10% fetal bovine serum (FBS) and 1% penicillin streptomycin (Pen-Strep). PNA Met1 cell cultures were cultured in DMEM high glucose medium supplemented with 10% FBS and 1% Pen-Strep. Both cell lines were maintained at 37 °C in a 5% CO2 humidified environment and subcultured upon reaching approximately 85% confluence. Immediately prior to injection, cells were rinsed three times with 1 × PBS, trypsinized, and pelleted twice and resuspended in serum-free RPMI medium to a concentration of approximately two million cells/mL.

**Brain Metastasis Mouse Models and In Vivo Experiments.** All animal experiments were performed ethically and in accordance with IACUC protocol approved by the University of Notre Dame IACUC committee. FVB and congenic Rag1−/− (C.129S7(B6)-Rag1<sup>tm1Snat)</sup>) mice were purchased from The Jackson Laboratory (Bar Harbor, ME). All mice were eight weeks or older prior to experimental procedures. In vivo brain metastases were formed by either injection of 100 μL (~200,000 cells) cell suspension via the right internal carotid artery or intra-cranial injection of 690 nL of ~70,000 cells (drug treatment experiments). Prior to and during injection of cancer cells, mice were anesthetized with isoflurane. Following surgery, mice received 100 μL subcutaneous injections of Baytril® (2.27%, Bayer HealthCare LLC, Animal Health Division), Ketoprofen® (1 mg/mL) and 1 mL of 0.9% NaCl. FVB mice injected with PNA Met1 cells were sacrificed after two weeks following cell injection, while the Rag1−/− mice injected with MDA-MB-231.Br cells were sacrificed between three to four weeks after injection. Two hours prior to sacrifice, mice were injected with 100 μL of 100 μg/mL 5-ethyl-2′-deoxyuridine (EdU, Life Technologies, Cat. No. 10639) via tail vein for labeling blood vasculature, animals were injected with 100 μL 10,000 MW Dextran, Alexa Fluor® 488 or Alexa Fluor® 594 (Life Technologies, Cat. No. D-22910 or D-22913) via tail vein five minutes prior to sacrifice when the brain was intended to be put through PACT or CUBIC tissue clearing. In instances when the brain was intended to be cleared by the ScaleAB protocol, cardiac perfusion with 10 mL or DiR (Sigma, Cat. No. 43608) was performed as described previously. Immediately prior to and during sacrificing, mice were anesthetized with isoflurane. Mice that did not receive a Dextran injection or were not perfused with DiR were perfused transcardially with 10 mL chilled 1 × PBS immediately followed by 10 mL chilled 4% paraformaldehyde (PFA). Mice that did receive a Dextran injection were not perfused. Brains were extracted, cut in half sagittally, and placed in 4% PFA for 24 hours at 4 °C with gentle rocking. For anti-angiogenic treatment experiments, Sorafenib (LC Laboratories, Woburn, MA) was administered to mice at a concentration of 50 mg/kg by intra-peritoneal injection once daily 10 days following metastasis induction. Sorafenib was diluted in Cremophore EL (Sigma)

**Tissue Clearing and Staining.** Slightly modified CUBIC and PACT tissue clearing protocols were used as follows for brain tissue clearing, with the exception of the Sorafenib treated brains. Following 24 hours fixation, brains were rinsed twice with 1 × PBS, sliced into 2 mm sagittal sections, and incubated in a hydrogel formulation (2 or 4% acrylamide in 1× PBS with 0.25% photoinitiator VA044 [Wako Chemicals]) at 4 °C gently rocking for three days. Prior to hydrogel polymerization, samples were degassed using a desiccation chamber, alternating between three 10-minute cycles of vacuum and nitrogen gas. Samples were polymerized by incubation at 37 °C for 3–4 hours. Polymerized hydrogel was decanted and samples were rinsed twice with 1 × PBS. Lipid removal from samples was then performed using either 8% SDS in 1 × PBS. Once samples became optically transparent after approximately 4–7 days, samples were washed for 24 hours in 1 × PBS before whole tissue staining (molecular phenotyping). For molecular phenotyping, all samples were first incubated in a 1:50 primary antibody dilution
(anti-Ms mAb GFAP (GA5), Cell Signaling Technology Technologies®, Cat. No. 3670s; anti-Rb mAb Cytokeratin 8 (EP1928Y), Abcam®, Cat. No. ab53280) in 0.1% Triton X-100 for 3 to 7 days with gentle rotating. Following primary antibody incubation, samples were washed for 24 hours in 0.1% Triton X-100 with minimum three rounds of buffer changes. All samples were then incubated in a 1:50 secondary antibody (goat anti-Rb or goat anti-Ms Alexa Fluor® 488, 594, or 647) dilution in 0.1% Triton X-100 for 3 to 7 days with gentle rotating. After secondary antibody incubation, EdU was detected per Click-iT EdU Alexa Fluor® 488 or 594 imaging kit (Life Technologies™, Cat. No. 10639) protocol with a 3–4 hour detection incubation period. Some samples were incubated in DAPI (0.025 mg/mL) for 12 hours with gentle rotating. Samples were washed one last time in 0.1% Triton X-100 for 24 hours with multiple buffer changes and then made optically transparent by incubation in CUBIC 2 reagent prepared as described previously for at least 2 hours prior to imaging. The brains of Sorafenib treated mice were cleared using ScaleAB methodology as previously described.

Confocal and Two-Photon Microscopy. All images were acquired using either the confocal or two photon setting on a commercial multiphoton laser scanning inverted microscope (Olympus FV1000) equipped with filter set (460–500, 520–560, 525–625, 650–700 nm) and a mode-locked Ti:sapphire laser (Maï Tai DeepSee 690–1040 nm, Spectra-Physics). Optical cleared and stained samples were immersed in CUBIC 2 reagent in a custom-made sample holder when imaged using a 10× ScaleView objective (XLPLN10XSVMP, Olympus USA; NA = 0.6 and WD = 8 mm) or placed on a coverslip when imaged using the 25× objective (XSLPLN25XGMP, Olympus USA; NA = 1.0 and WD = 8 mm). Use of confocal versus multiphoton was dictated by which method better excited the Alexa fluorophores, which depended on fluorophore vendor and imaging depth. When acquiring images to be stitched, MATL was used in the Olympus software to program 10% overlap between imaging stacks.

Image Processing and Segmentation. Background removal. Auto-fluorescence in mouse brains results in a strong and inhomogeneous background in the acquired 3D images. Such inhomogeneous background (noise) causes difficulties to segmentation and visualization of the 3D images. We developed a new approach that combines the spatial filtering method and optimization-based methods for this background removal problem. First, we applied percentile filtering with a window size that is slightly bigger than the size of the smallest object (e.g., the size of a cell) in the image, to estimate a rough background. Then, we used unsupervised one-class learning to detect errors in this rough estimation. Finally, these errors were corrected in the re-estimation process and the refined background estimation was obtained for generating a noise-free image. The processing speed of our new background removal method is comparable to the rolling ball algorithm and yields the state-of-the-art accuracy. More details and validations can be found.

Voxel-level segmentation. We utilized information from multiple channels (e.g. K8, DAPI, GFAP, and EdU) for segmentation. For this purpose, we formulated the voxel-level segmentation problem as a classification problem. Several classifiers were trained to determine whether a voxel belongs to a specific type of foreground (tumor cells, astrocytes, blood vessels, etc) or the background based on multi-channel features. These classifiers were then applied to every voxel in the 3D image to generate the segmentation.

(1) Multi-channel feature extraction: The classification accuracy relies heavily on the quality of the extracted features. In order to utilize multi-channel information, our multi-channel feature extraction procedure for the voxels consists of two main steps. (i) Extracting a feature vector in each channel. As in, the following features are extracted for every voxel in each channel to represent its appearance and texture: Intensity, gradient magnitude, eigenvalues of the Hessian matrix, and eigenvalues of structure tensor; (ii) concatenating feature vectors from different channels to form a multi-channel feature vector. (2) Voxel classification: After the feature extraction process, training data were labeled by human experts and used to train four random forest classifiers that were designed to classify tumor cells, astrocytes, proliferating cells, and blood vessels. Each classifier has 200 trees and 2 candidate features in each node. These classifiers are then applied to every voxel in the 3D image to generate segmentation results.

Structural-level segmentation. Since tumor cells tend to form dense clusters, to eliminate false-positives, cell clusters whose volumes are larger than a threshold in the voxel-level segmentation of tumor cells were identified as tumor clusters. The volume of each cell cluster was approximated by the volume of its connected component in the voxel-level segmentation. The threshold for large clusters was selected by a human expert for each 3D image. When K8 staining was used, each cell cluster that contains K8 signal was immediately identified as a tumor cluster regardless of its size.

Image Quantification. Based on the structural-level segmentation and voxel-level segmentation, we performed the following quantifications. (1) Proliferation ratio: By assuming that every cell of a specific type has an average volume, the proliferation ratio of each tumor cluster can be determined approximately as the ratio of the volume of proliferating cells inside the tumor to the volume of the tumor cluster. The volume of proliferating cells was computed based on their voxel-level segmentation and the volume of the tumor cluster was computed as describe above. (2) Volume of surrounding astrocytes (astrogliosis): For each tumor cluster, we define its surrounding space as consisting of all the voxels that satisfy the following two conditions: (a) It is outside the tumor cluster, and (b) its closest distance to the tumor surface is smaller than a chosen value \( d \) (the average diameter of an astrocyte is \( 24 \) μm. Therefore we set \( d = 24 \) μm to survey the single layer of astrocytes surrounding the tumor for astrocytes). The surrounding space was calculated in two steps: (i) dilate the cluster region in the original image in a spherical manner with a radius \( d \); (ii) subtract the original cluster region from the dilated region. Then the volume of the surrounding astrocytes can be easily calculated. (3) Zone analysis: Zone analysis was performed in
3D Volumetric Data Presentation. 3D images were obtained by stacking up and aligning 2D image slices based on minimizing the mean squared error (MSE) between aligned regions in consecutive slices using a custom MATLAB code and XUVStitch (http://www.xuvtools.org). All surface generated data and images of original data or surface generated data were created using IMARIS software (Bitplane).

Raw quantification data were extracted by using MATLAB, and statistical analysis was performed in R studio. P < 0.05 (two-tailed) was considered statistically significant.

References

**Acknowledgements**

We would like to thank Dr. Charles Tessier at Indiana University School of Medicine South Bend and Richard Heil-Chapdelaine at Olympus USA for invaluable technical support. We would like to thank Dr. Calli A. Versagli for technical support and Zhang Lab members for insightful discussions of this project. This work was partially supported by NIH Pathway to Independence Award 5R00CA158066-05 (SZ), NIH 1R01CA194697-01 (SZ), Walther Cancer Foundation Advancing Basic Cancer Research Grant II (SZ), Department of Defense W81XWH-15-1-0021 (SZ), Indiana CTSI core pilot fund (SZ), and NSF Grant CCF-1217906 (DZC). Dr. S. Zhang is the Nancy Dee Assistant Professor in Cancer Research at University of Notre Dame.

**Author Contributions**


**Additional Information**

Supplementary information accompanies this paper at http://www.nature.com/srep

Competing financial interests: The authors declare no competing financial interests.

**How to cite this article**: Guldner, I. H. et al. An Integrative Platform for Three-dimensional Quantitative Analysis of Spatially Heterogeneous Metastasis Landscapes. *Sci. Rep.* 6, 24201; doi: 10.1038/srep24201 (2016).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/